Nicolas Correa S.A. (0FDN)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 9.800 |
|---|---|
| 52-week range | 8.900 – 11.150 |
| Return, 1 month / 3 months | −3.9% / +3.4% |
| Return, 1 year / 3 years | +0.5% / +81.1% |
| Trend | Uptrend |
| RSI (14) | 50 |
| Volatility (1 year) | 31.1% |
| Worst drawdown (1 year) | -21.2% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | 2.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nicolas Correa S.A. is a Spanish machine tool builder based in Burgos. It designs and manufactures milling machines and machining centres, including bridge-type and gantry models, along with related components and services. Its customers are industrial manufacturers that use these machines for cutting and shaping metal parts, with activity in sectors such as aerospace, energy, railway and general engineering. The company also provides maintenance, retrofitting and technical support for its installed machines.
Nicolas Correa S.A. trades under the code 0FDN on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nicolas Correa S.A. (0FDN) trades on the London Stock Exchange in UK. It last closed at EUR 9.800 on 27 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 2,066 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.5% and over the last three months it rose 3.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.2% | ||
| From 52-week high | -7.1% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.4% | ||
| 6-month return | -0.5% | ||
| 12-month return, skipping the last month | 4.6% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.2% | ||
| Liquidity | 8 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 28.3% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.5% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.7% |
|---|---|
| 1 month | −3.9% |
| 3 months | +3.4% |
| 6 months | −0.5% |
| 1 year | +0.5% |
| 3 years | +81.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 9.769 / 9.682 |
|---|---|
| Golden / death cross (60 days) | Golden, 13 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.180 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 May 2026 | EUR 0.2430 |
| 5 Jun 2025 | EUR 0.2430 |
| 2 May 2024 | EUR 0.2187 |
| 4 May 2023 | EUR 0.1863 |
| 29 Apr 2022 | EUR 0.1620 |
| 7 May 2021 | EUR 0.1377 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.